NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Cupid's Q4FY26 Performance Overshadowed by Concerns Over West Asia Conflict and Raw Material Costs

Shares of Cupid plummeted by over 5 per cent in Tuesday's trade, despite the condom-maker reporting its strongest-ever quarterly performance for Q4FY26. The stock declined 5.04 per cent or Rs 6.09 to trade at Rs 114.75 on the National Stock Exchange (NSE).

Cupid announced last week that it had achieved the best quarterly performance in the company's history for the quarter ended March 31, 2026. The company's revenue and net profit surpassed its FY26 guidance of Rs 335 crore and Rs 100 crore, respectively. The strong performance was attributed to strong execution, sustained demand momentum, and traction across key business segments.

The company's diversified portfolio across healthcare, wellness, diagnostics, and FMCG categories continued to strengthen the overall business mix. Male condoms remained the largest contributor to revenue during FY26 at around Rs 181.11 crore, followed by female condoms and newly launched FMCG products.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

However, valuation concerns continued to weigh on investor sentiment. Research Analyst Nitant Darekar at Bonanza noted that Cupid is priced for perfection with a TTM P/E near 200X and 43X book value, leaving zero margin for slippage in an uncertain global environment.

CompanyTTM P/E Multiple
Procter & Gamble Hygiene and Health Care25X
Gillette India20X
Emami30X
Honasa Consumer35X
Bajaj Consumer Care27X
Cupid Ltd200X

The comparison data available on the NSE showed FMCG companies trading at significantly lower valuation multiples.

On the technical outlook, Senior Technical Research Analyst Virat Jagad at Bonanza noted that Cupid Ltd has witnessed a sharp correction after facing strong resistance near the 130-133 zone, indicating profit booking following the recent breakout rally. The stock has slipped below its short-term moving average, while RSI has dropped near the 40 mark, reflecting weakening momentum in the near term.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The concerns over rising raw material costs also come amid mounting global supply disruptions linked to the Iran conflict. Last month, Karex, the world's largest condom manufacturer, had said it may raise prices by up to 30 per cent or more if the conflict continues to disrupt raw material supplies. Karex's chief executive Goh Miah Kiat had said production costs had risen sharply following disruptions in global oil supply chains after Iran threatened action in the Strait of Hormuz in response to US and Israeli airstrikes.

Investor Takeaway

Investors should be cautious of potential disruptions in the supply chain due to the West Asia conflict.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.